Short answer
Liquidia Corp (LQDA) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $172M (up 1842.7% year over year) with net income of $75M.
Q2 2026 key financials · XBRL
- Revenue
- $172M
- +1842.7% YoY · +29.2% QoQ
- Net income
- $75M
- +279.7% YoY · +41.4% QoQ
- Operating margin
- 49.8%
- EPS (diluted)
- $0.74
- +251.0% YoY · +42.3% QoQ
Source: XBRL data from the Liquidia Corp (LQDA) Q2 2026 10-Q on SEC EDGAR. USD.
Liquidia Corp Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $171.7M, up 1,843% YoY from $8.8M, driven by YUTREPIA product sales
- Q2 net income $74.7M vs $41.6M loss YoY; operating margin 49.8% vs (424.5)%
- Best performer YUTREPIA sales $170.4M vs $6.5M YoY; service revenue fell to $1.3M from $2.3M
- Six-month operating cash flow $133.2M vs $(70.2)M YoY; cash and equivalents $284.2M at June 30
- Outlook: sufficient liquidity beyond one year; risks include FDA approval, litigation, YUTREPIA sustainability, and L606 spending
Risk Factors
- Newly cited tax risk: OBBBA changes domestic R&D deduction rules after December 31, 2024
- Most material legal risk: United Therapeutics seeks injunctions that could remove YUTREPIA from the market or its PAH and PH-ILD indications
- Regulatory risk: Sandoz controls FDA-approved Treprostinil Injection manufacturing and related healthcare compliance
- Near-term commercial risk: YUTREPIA remains the company’s only approved product, commercialized since June 2025
- Financial risk: HCR facility requires a $15.0 million minimum cash balance and permits collateral foreclosure after uncured default
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Liquidia Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.